Trials / Completed
CompletedNCT02914665
A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 308 (actual)
- Sponsor
- Stealth BioTherapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2 randomized, double-blind, placebo-controlled study to evaluate the cardiac and renal effects of short term treatment with elamipretide in patients hospitalized with congestion due to heart failure
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | elamipretide | 20 mg elamipretide administered intravenously once daily for 7 consecutive days |
| DRUG | Placebo | Placebo administered intravenously once daily for 7 consecutive days |
Timeline
- Start date
- 2016-10-20
- Primary completion
- 2017-11-27
- Completion
- 2017-11-27
- First posted
- 2016-09-26
- Last updated
- 2020-07-28
Locations
46 sites across 10 countries: Belgium, Bulgaria, France, Hungary, Latvia, Netherlands, Poland, Serbia, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02914665. Inclusion in this directory is not an endorsement.